Tag Archives: Mike Lanthier

True Pharma Innovation Lies in Quality — not Quantity — of Approvals, say FDA analysts

We’re already embroiled in the annual speculation game about whether FDA approvals this year will keep pace with last year’s near-record of 39 new molecular entities (NMEs) brought to market. The tally is closely watched as a sign of the state of biopharmaceutical innovation and the health of the pharmaceutical industry and biomedical research enterprise.
Posted in Biotech, FDA, Regulatory | Also tagged , , , , , , | Leave a comment
  • Categories

  • Meta